Sandy Hwang Fang

Dr. Sandy Hwang Fang

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SFSandy Hwang Fang
Sandy Hwang Fang
MPMihaela Plesa
Mihaela Plesa
ECEvie H Carchman
Evie H Carchman
NCNicole A Cowell
Nicole A Cowell
ESEmily Staudt
Emily Staudt
CTCornelia L Trimble
Cornelia L Trimble
Ablation or surgical excision is the typical treatment of anal high-grade squamous intraepithelial lesions (HSIL). Recurrences are common due to the persistence of underlying human papillomavirus (HPV) infection. Additional well-tolerated and effective non-surgical options for HPV-associated anal disease are needed. This 3+3 dose escalation Phase I clinical trial evaluated the safety and tolerability of artesunate suppositories in the treatment of patients with biopsy-proven HSIL. The maximal tolerated dose was 400 mg, administered in 3 cycles. All adverse events associated with the use 200- and 400-mg artesunate suppositories were Grade 1. At the 600-mg dose, patients experienced clinically significant nausea. Artesunate suppositories are a safe treatment option for anal HSIL.

1 August 2015 in The American Journal of Surgery
Verified
Journal Article
Closed access
ESEric B. Schneider
Eric B. Schneider
ASAparajita Singh
Aparajita Singh
JSJennifer Sung
Jennifer Sung
BHBenjamin Hassid
Benjamin Hassid
SSShalini Selvarajah
Shalini Selvarajah
ALAnne O. Lidor
Anne O. Lidor

1 January 2010 in Annals of Surgery
Verified
Journal Article
Closed access
SFSandy Hwang Fang
Sandy Hwang Fang
JGJulie A. Guidroz
Julie A. Guidroz
YOYunxia O'Malley
Yunxia O'Malley
GLGeeta Lal
Geeta Lal
SSSonia L. Sugg
Sonia L. Sugg
RWRonald J. Weigel
Ronald J. Weigel
Objective: We sought to examine abnormal parathyroid glands for the presence of stem cells. Summary Background Data: Cancer stem cells have been identified in cancers from a variety of tissues as a CD44+/CD24− cell population. We hypothesize that stem cells (SC) may also be involved in the pathogenesis of benign clonal expansion characteristic of hyperparathyroidism (HPT). Methods: Under institutional review board approval, parathyroid tissue was obtained from 20 patients with HPT and analyzed by fluorescence-activated cell sorting (FACS) for the CD44+/CD24− cell population. Immunohistochemistry (IHC) with CD44 antibody was correlated with FACS results. Results: Parathyroid tissue was obtained for FACS analysis from 25 enlarged parathyroid glands from 20 patients, 17 with primary HPT, and 3 with secondary HPT. The average percent of SC defined as CD44+/CD24− population was 10.93% for enlarged parathyroid glands. IHC using CD44 antibody was performed on 27 abnormal parathyroid glands and 7 normal parathyroid gland biopsies from the same patients. Although IHC was not as sensitive as FACS, comparison of IHC and FACS results for 24 abnormal glands gave a correlation coefficient of 0.52, which was statistically significant (P = 0.01, Spearman rank). By IHC, 13 of 27 abnormal glands stained 1+ to 3+ (average, 0.93) compared with no CD44 staining in normal glands, which was statistically different (mean IHC of 0 vs. 0.93, P = 0.03, Wilcoxon). Conclusions: These novel findings demonstrate expansion of a resident cell population that expresses SC markers in abnormal parathyroid glands from patients with HPT. Our results suggest that clonal expansion of a resident SC population occurs in the pathogenesis not only of cancer, but also in benign parathyroid tumors occurring in HPT.

27 February 2020 in Endoscopy
Verified
Journal Article
Open access
PDF file
SNSaowanee Ngamruengphong
Saowanee Ngamruengphong
SMSonmoon Mohapatra
Sonmoon Mohapatra
TRThomas M. Runge
Thomas M. Runge
EPEduardo Paredes
Eduardo Paredes
SFSandy Hwang Fang
Sandy Hwang Fang
A 66-year-old man with a history of lower rectal adenocarcinoma and robotic-assisted low anterior resection with creation of a diverting ileostomy, presented with complete stenosis of the coloanal anastomosis ([Fig. 1 a]). Rendezvous recanalization of the coloanal obstruction was planned ([Video 1]). Video 1 Recanalization of a complete coloanal anastomotic obstruction using a combined antegrade-retrograde rendezvous technique. A pediatric colonoscope was advanced through the ileostomy toward the distal colon where complete obstruction was identified at the coloanal anastomosis ([Fig. 1 b]). As the colonoscope could not be advanced to the blind end, the blunt end of an injection needle was used to push at the blind end to facilitate identification of the puncture site ([Fig. 2 a]). Using transillumination and digital palpation, the coloanal anastomosis was punctured from the anal side using a trocar ([Fig. 2 b]). A 0.035-inch Jagwire (Boston Scientific, Marlborough, Massachusetts, USA) was advanced through the trocar and captured using a snare. The guidewire was pulled out and both ends of the guidewire were captured. The coloanal stricture was dilated using a controlled radial expansion balloon ([Fig. 3 a]). An 18 × 153-mm esophageal fully covered metal stent was advanced from the anal side and deployed across the coloanal stricture ([Fig. 3 b]). The stent was secured with two 2-0 silk sutures. To maintain patency of the anastomosis in the event of stent migration, a colonic decompression tube was advanced over the guidewire and both ends were sutured together. Computed tomography scan confirmed correct position of the stent ([Fig. 4]). Sigmoidoscopy was performed at 4 weeks for stent removal. The anastomosis was patent and had healed ([Fig. 5]). Ileostomy reversal was successfully performed 5 days later. Rendezvous recanalization of complete coloanal obstruction is a potential alternative to revision surgery, which is difficult and has high morbidity. When endoscopic ultrasound-guided techniques for accessing the proximal colon are not possible, combination of transillumination and digital palpation is a viable option. Endoscopy_UCTN_Code_TTT_1AQ_2AF Publication Date: 27 February 2020 (online) © Georg Thieme Verlag KG Stuttgart · New York

1 September 2014 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
KKK. Kato
K. Kato
HSH. Shoji
H. Shoji
TKT. Kakizaki
T. Kakizaki
KHKazufumi Honda
Kazufumi Honda
AKA. Kakimoto
A. Kakimoto
KFK. Furuta
K. Furuta
Aim: Monitoring of tumor biology provides pivotal information for suitable therapy. Circulating tumor cells (CTCs) released into the blood stream from primary tumor and metastases may reflect current tumor status. The ClearCell FX system (Clearbridge Biomedics, Singapore), which uses a label-free inertial microfluidics approach based on biomechanical properties, is able to capture CTCs independent of EpCAM expression. We investigated the tumor biology by performing genomic profiling of CTCs using next-generation sequencing (NGS). Methods: Patients with advanced gastric and colorectal cancer were enrolled in this study. We collected 10mL of blood from each patient. CTCs were extracted by using the Clearcell FX system. DNA was prepared immediately after isolation, after a week's culture with RepCellTM (CellSeed) which was a temperature-responsive cell cultureware. Whole genome amplification (WGA) was performed by using REPLI-g Single Cell Kit (Qiagen), and NGS was performed by using Ion Ampliseq (LifeTechnology). Cells were enumerated using cytokeratin staining and immunocytochemical analysis. At the same time, we prepared DNA not only from peripheral blood mononuclear cells but also from plasma (cell-free DNA). Results: 8 patients were enrolled; 6 had colorectal cancer and 2 had gastric cancer. Median of CTC count was 6/mL (ranges 3 to 14). On the other hand, the number of CTCs collected by CellSearch ranged from 0 to 1/7.5mL. In these 8 cases, either right after isolation or after 1 week of culture, DNA derived from CTCs was successfully prepared by WGA. NGS was successfully performed with WGA treated DNA from CTCs and related materials. Conclusions: By using ClearCell FX System's label-free technology, we were able to capture a larger number of CTCs from patients with gastric and colorectal cancer than with using the CellSearch system. NGS from CTCs and related materials can be performed successfully. Disclosure: A. Kakimoto: I am a employee of SRL Inc.; T. Sakuma: I am a employee of Mitsui Knowledge Industry Co and Ltd.; S. Fang: I am a employee of Clearbridge Accelarator; A. Wu: I am a employee of Clearbridge Bio Medics; C.T. Lim: I have stock of Clearbridge Biomedics Pte Ltd. All other authors have declared no conflicts of interest.

13 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CACynthia Araradian
Cynthia Araradian
MEMariah Erlick
Mariah Erlick
EHEmmett Hunnicutt
Emmett Hunnicutt
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
EREmily Burke Rivet
Emily Burke Rivet
SFSandy Hwang Fang
Sandy Hwang Fang
Background: Anal cancer screening has allowed for the diagnosis of early-stage anal cancers; however, guidelines for the treatment of early anal cancers remain mixed given the scarcity of clinical trials and data. Management ranges from chemoradiation therapy to local surgical excision. Methods: This paper’s objective is to clarify the definition of early anal cancer and its management. Approval for this systematic review was obtained through PROSPERO [CRD42022304327]. Three independent reviewers screened the studies and performed data analysis, with conflicts resolved by a fourth reviewer. All information is presented according to the Preferred Reporting Item for Systematic Reviews and Meta-Analysis (PRISMA). The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) criteria were used to assess the certainty of the evidence. Results: The MEDLINE, EMBASE and Cochrane databases were queried with 628 articles screened. A total of 15 articles were selected for inclusion. Early anal cancer was most often defined as T1-2N0M0 anal cancer but also included Superficially Invasive Squamous Cell Carcinoma (SISCCA). There were various treatments assessed for outcomes including local excision, chemoradiation, and radiation. The studies reported overall survival, cancer-specific survival, recurrence-free survival, and/or colostomy-free survival, leading to significant heterogeneity amongst the studies. No meta-analysis was possible. Conclusions: Poor-quality studies exist for the evaluation of the most effective treatment modality for early anal cancer. Surgical excision alone with adequate margins has equivocal results, but data is poor. Chemoradiation is successful but may be overtreatment. Randomized controlled studies are needed, as screening will result in earlier anal cancer diagnoses.